Replies to post #214 on Equity Field Notes from temporal sources

[DanWebzster]

LMCNF is a 2-yr old miner that has rolled up special situation cast-off mines to become a mid-tier producer.

Leagold should produce ~450,000 toz gold in 2018 with an AISC of 930/oz

Proven and probable reservices = 5.4mn toz

MC as of 6/18 ~$557mn with 284mn shares outstanding. The market values LMCNF at $103.08 / toz

Comparable gold miners are valued at least 4.9x LMCNF

One explanation is Gold stock ETFS have not yet recognized this company as a mid-tier producer. When and if they do, there will be institutional equity appreciation.

[DanWebzster]

ADVM ( and AAV Gene Therapy)

ADVM is conducting a Ph1 dose escalaton study using AAV to deliver Alpha-1 Antitrypsin gene for early onset emphysema.

If their serotype-payload cassette-immunogenic purity platform work in this application, they may have a blockbuster platform on their hands.

On 3/31/18 their cash runway thru 2019


On Gene Therapy:

Gene therapies target monogenic diseases (those diseases with a single damaged or missing gene)

12/19/17, ONCE received the first FDA approval for a gene therapy. Luxterna is treats a congenital condition of the eye. Luxterna costs $850K to treat both eyes. Luxterna delivers a gene rather than modifying or editing one.

Luxterna ues adeno-associated virus (AAV ) as a vector to deliver this gene. AAV has low immunogenicity and is customizable with regard to its payload.

For companies researching AAV, the secret sauces are the specific serotype, the expression cassette and the purity of the vector preparation. Serotype determines tissue affinity.

[DanWebzster]

MESO (update)

Q3/18 expecting 180-day follow-on data to Ph3 study that successfully met its primary endpoint

The expectation is to have the first industrial mfred allogenic mesenchymal lineage cell-based product in the U.S.

Although there is competition, it's very likely that there will be a niche for this GVHD treatment.

Cash runway now extends into Q4/19 and would likely get MESO thru a PDUFA decision.